AgingResearch.NewsJoin free

Kidney, cardiovascular (CV), and mortality outcomes

Disease

1 paper1 finding

  • Human trial1

Associations

1

Semaglutide

downin humans1

1 study

  1. Semaglutide lowers the risk of kidney, cardiovascular (CV), and mortality outcomes in humans.

    “In FLOW, semaglutide reduced the risk of kidney, cardiovascular (CV), and mortality outcomes in people with type 2 diabetes (T2D) and chronic kidney disease (CKD).”

    Human trialin people with type 2 diabetes and chronic kidney diseasesubcutaneous1.0 mgonce-weeklyn = 3,533

    Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial

    ADA Scientific Sessions 2025 abstract13 Jun 2025

More on Semaglutide

Latest

Related